Last reviewed · How we verify
Placebo of Dapagliflozin
Placebo of Dapagliflozin is a Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently in Phase 3 development for Control arm in dapagliflozin clinical trial (indication depends on parent trial).
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.
This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in dapagliflozin clinical trial (indication depends on parent trial).
At a glance
| Generic name | Placebo of Dapagliflozin |
|---|---|
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
A placebo is an inert substance used as a control in clinical trials to establish the true efficacy of the active drug (dapagliflozin) by comparison. Patients receiving placebo will experience no pharmacological effect from the study treatment itself, allowing researchers to measure the actual therapeutic benefit of dapagliflozin against baseline disease progression and placebo response.
Approved indications
- Control arm in dapagliflozin clinical trial (indication depends on parent trial)
Common side effects
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus (PHASE4)
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (PHASE2)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (PHASE4)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Dapagliflozin CI brief — competitive landscape report
- Placebo of Dapagliflozin updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI
Frequently asked questions about Placebo of Dapagliflozin
What is Placebo of Dapagliflozin?
How does Placebo of Dapagliflozin work?
What is Placebo of Dapagliflozin used for?
Who makes Placebo of Dapagliflozin?
What development phase is Placebo of Dapagliflozin in?
Related
- Manufacturer: Hospital de Clinicas de Porto Alegre — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Control arm in dapagliflozin clinical trial (indication depends on parent trial)
- Compare: Placebo of Dapagliflozin vs similar drugs
- Pricing: Placebo of Dapagliflozin cost, discount & access